|4.||Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia)
|5.||Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell)
|1.||Klein, George: 12 articles (01/2015 - 06/2002)|
|2.||Hoelzer, Dieter: 12 articles (12/2014 - 04/2004)|
|3.||De Falco, Giulia: 10 articles (01/2016 - 12/2009)|
|4.||Leoncini, Lorenzo: 10 articles (01/2016 - 12/2009)|
|5.||Staudt, Louis M: 10 articles (02/2015 - 06/2006)|
|6.||Salamon, Daniel: 9 articles (01/2016 - 01/2003)|
|7.||Rosenwald, Andreas: 9 articles (02/2015 - 06/2006)|
|8.||Bellan, Cristiana: 8 articles (01/2016 - 12/2009)|
|9.||Weisenburger, Dennis D: 8 articles (02/2015 - 06/2006)|
|10.||Delabie, Jan: 8 articles (02/2015 - 12/2004)|
|1.||rituximab (Mabthera)FDA Link
09/01/2014 - "Prolonged low intensity EPOCH-rituximab has improved toxicity in Burkitt lymphoma compared with standard short, high intensity therapy."
02/01/2007 - "In fact, the combination is more effective than rituximab alone in inhibiting proliferation of Daudi Burkitt lymphoma cells in the presence of second antibody, and at least equally effective to rituximab in the absence of crosslinking. "
07/09/2015 - "AMC 048: modified CODOX-M/IVAC-rituximab is safe and effective for HIV-associated Burkitt lymphoma."
01/01/2014 - "We postulated that, radiation-induced modulation of CD20 surface levels may play a crucial and central role in determining the relative efficacy of rituximab and tositumomab in treating Burkitt's lymphoma disease. "
02/01/2014 - "Rituximab is associated with improved survival in Burkitt lymphoma: a retrospective analysis from two US academic medical centers."
|2.||Cyclophosphamide (Cytoxan)FDA LinkGeneric
09/01/2005 - "Although cyclophosphamide based regimens can produce remission rates approaching 60 to 80% in endemic Burkitts lymphoma, relapses and refractory disease are fairly common in developing countries, due to advanced stage disease and cost-constraints in the implementation of optimal chemotherapeutic protocols. "
01/01/2011 - "Cyclophosphamide monotherapy in children with Burkitt lymphoma: a study from the French-African Pediatric Oncology Group (GFAOP)."
07/01/1992 - "The origins of current multi-agent regimens stem both from early experience with cyclophosphamide in endemic Burkitt's lymphoma and from therapeutic studies of acute lymphoblastic leukaemia. "
01/01/2013 - "In Malawi the treatment for all stages of Burkitt's lymphoma is intravenous cyclophosphamide (40 mg/kg on day 1 and oral cyclophosphamide 60 mg/kg on days 8, 18 and 28). "
01/01/2011 - "Preliminary observations on the efficacy in Burkitt lymphoma (BL) of a cyclophosphamide monotherapy (CPM) have been published. "
|3.||Methotrexate (Mexate)FDA LinkGeneric
12/01/2002 - "This study was designed to establish Burkitt's lymphoma methotrexate resistant cell strain--Namlwa 12/MTX and study its resistant mechanism. "
01/01/2012 - "Our findings confirm the favorable prognosis of children with Burkitt's lymphoma even when treated with intermediate doses of methotrexate (500 mg/m2). "
11/01/2009 - "High-dose methotrexate (HD-MTX) is an important treatment for Burkitt lymphoma, but can cause hepatic and renal toxicity when its clearance is delayed. "
12/01/2006 - "Therapy regimens for adults with Burkitt lymphoma have been developed by modifying second-generation pediatric protocols, and few investigators have used the third-generation pediatric regimens that include higher doses of methotrexate and additional agents. "
09/01/1984 - "Using methotrexate cell synchronization, we successfully analyzed chromosomal preparations of 40 lymph node biopsies and one bone marrow sample from 44 patients with non-Hodgkin's, non-Burkitt's lymphoma. "
|4.||Vincristine (Oncovin)FDA LinkGeneric
11/01/1992 - "In this study, the patterns of cell death induced by vincristine in the intestinal crypts of mice and in a human Burkitt's lymphoma cell line were investigated by light and electron microscopy. "
11/01/2015 - "Outcome is unchanged by adding vincristine upfront to the Malawi 28-day protocol for endemic Burkitt lymphoma."
01/01/2012 - "These results indicated that SAL possesses the potential to enhance the anticancer activites of low-concentrations of vincristine by the down-regulating the MRP1 gene expression to inhibit the multidrug resistance by binding to the target ligand Gb3-glycosphingolipid on Burkitt's lymphoma cells."
03/01/1998 - "To understand how expression of one allele occurs, two multidrug resistant sublines were isolated by exposing a Burkitt lymphoma cell line to increasing concentrations of vincristine. "
11/01/1992 - "Cell death induced by vincristine in the intestinal crypts of mice and in a human Burkitt's lymphoma cell line."
|5.||Doxorubicin (Adriamycin)FDA LinkGeneric
09/01/2004 - "Signal transduction pathways in Burkitt's lymphoma cell lines BL41 and DG75 with different sensitivity to doxorubicin."
12/01/2013 - "A multicenter phase II study incorporating high-dose rituximab and liposomal doxorubicin into the CODOX-M/IVAC regimen for untreated Burkitt's lymphoma."
01/01/2009 - "A strong correlation between IL-6 secretion, measured by ELISA, and resistance to doxorubicin as ionizing radiations was observed in the multiple myeloma U266 and the Burkitt's lymphoma Daudi and Namalwa cells. "
11/02/1999 - "In the present study, we showed that the topoisomerase II inhibitor of widely used anticancer drugs etoposide and doxorubicin activated wt p53 in BL2, a Burkitt's lymphoma cell line which overexpressed MDM2. "
02/01/1979 - "The effects of hyperbaric oxygen (HPO) exposure on the cytotoxicity of Adriamycin (ADM) and nitrogen mustard have been examined in Burkitt's lymphoma cells (P3J) in vitro. "
|6.||Cytarabine (Cytosar-U)FDA LinkGeneric
11/01/2006 - "We show that, remarkably, MTX enhances incorporation and cytotoxicity of ara-C through regulation of dCK activity in Burkitt's lymphoma cells. "
10/01/2014 - "A 5-year-old girl who had undergone liver transplantation was scheduled for treatment with high-dose cytarabine for a Burkitt lymphoma. "
11/01/2015 - "Liposomal cytarabine in prophylaxis or curative treatment of central nervous system involvement in Burkitt leukemia/lymphoma."
10/01/2000 - "CCLSG-NHL960 protocol for LB lymphomas and intensive multiagent regimens for LC lymphomas produced favorable response rates, but the effect of the high-dose Ara-C regimen for Burkitt's lymphoma was not determined. "
07/01/1993 - "Chemotherapy with cytosine arabinoside in a child with Burkitt's lymphoma on maintenance hemodialysis and hemofiltration."
04/01/2002 - "The role that Epstein-Barr virus plays in nasopharyngeal carcinoma and Burkitt's lymphoma has been under intense study for many years. "
01/01/1989 - "Further studies are needed to define more accurately the part played by EBV in Burkitt's lymphoma and nasopharyngeal carcinoma. "
01/01/1978 - "Epstein-Barr virus-regulation studies on somatic-cell hybrids derived from the fusion of Burkitt's lymphoma and nasopharyngeal carcinoma cells with human or mouse partners."
06/21/1971 - "Studies on nasopharyngeal carcinoma and Burkitt lymphoma by immunofluorescence."
01/01/2015 - "We first compared EBNA1 ChIP-Seq patterns in four different EBV-positive cell types, including Burkitt lymphoma (BL) cells, nasopharyngeal carcinoma (NPC) cells, and lymphoblastoid cell lines (LCLs). "
|8.||Etoposide (VP 16)FDA LinkGeneric
01/01/2005 - "In this study we show that the heterologous expression of the previously uncharacterised Herpesvirus pan BHRF1 in the human Burkitt's lymphoma cell line Ramos-BL provides similar anti-apoptotic functions to that of EBV BHRF1 in response to apoptosis triggered by serum withdrawal, etoposide treatment and ultraviolet (UV) radiation. "
01/01/2011 - "EBV interferes with the sensitivity of Burkitt lymphoma Akata cells to etoposide."
08/31/1998 - "Resistance to etoposide-induced apoptosis in a Burkitt's lymphoma cell line."
01/01/1987 - "Three different cell line generated tumours (T-ALL L735, Hodgkin cell line L540 and Burkitt Lymphoma Line BJAB) were treated with four different drugs (CY, ADM, VCR, VP16). "
12/19/2013 - "The ectopic expression of DDR1 significantly increased the survival of collagen-treated DG75 Burkitt lymphoma cells, following etoposide treatment. "
01/01/1978 - "Epstein-Barr virus-associated and other antiviral antibodies during intense BCG administration to patients with Burkitt's lymphoma in remission."
12/01/2006 - "Human D430B cells or Raji Burkitt lymphoma cells were incubated in vitro with different amounts of commercially available USPIO-anti-CD20 antibodies and cell pellets were stratified in a test tube. "
12/01/2005 - "injection of anti-CD70 antibodies also inhibited the growth of CD70+ Burkitt's lymphoma cells in severe combined immunodeficient mice but did not inhibit the growth of CD70- Burkitt's lymphoma cells. "
04/01/2003 - "In addition, we describe a short-time in vitro induction model for somatic hypermutation by using the BL2 Burkitt's lymphoma cell line stimulated by a combination of antibodies directed against different surface receptors. "
07/01/1994 - "Cocapping of CD19 and CD77 on Burkitt's lymphoma-derived Daudi cells with anti-CD19 antibodies indicates that CD19 and CD77 are associated on the B cell surface. "
04/10/1995 - "Earlier studies have shown that Burkitt's lymphoma (BL) cell lines can be divided into 2 major groups: group I, which retain the original BL biopsy phenotype with expression of CD10 and CD77 antigens and lack of B-cell activation markers, and group III, which, after several in vitro passages, progress toward an "LCL-Like" phenotype with loss of CD10 and C77 expression and up-regulation of B-cell activation antigens. "
01/01/1988 - "In this study Burkitt lymphoma cell lines, previously typed according to the EBV viral genomes they carry, as well as some matching lymphoblastoid cell lines were examined by immunoblotting for the expression of both EBNA1 and EBNA2 antigens. "
05/01/1983 - "Studies on the B lymphoblast antigen No. 1 (BB-1) on a series of Burkitt lymphoma lines differing in the expression of the EBV/C3 receptor complex."
10/01/1967 - "Antigen(s) in the cell line which was reactive by immunofluorescence was similar or identical to that found in several other Burkitt tumor cell lines in previous studies. "
01/01/2016 - "Clonality Analysis of Immunoglobulin Gene Rearrangement by Next-Generation Sequencing in Endemic Burkitt Lymphoma Suggests Antigen Drive Activation of BCR as Opposed to Sporadic Burkitt Lymphoma."
|1.||Drug Therapy (Chemotherapy)
06/01/2014 - "[Low-dose chemotherapy is highly effective in adults with sporadic or HIV-associated Burkitt's lymphoma]."
12/01/2013 - "He had Burkitt lymphoma at the age of 3 years and received chemotherapy (non-Hodgkin's lymphoma-Berlin-Frankfurt-Milan-90 protocol plus rituximab), which induced complete remission over the following two years. "
10/01/2011 - "After the first cycle of chemotherapy a complete remission of Burkitt?s lymphoma was achieved. "
12/01/2008 - "Short-term intensive chemotherapy regimens have substantially improved the prognosis of pediatric patients with Burkitt lymphoma (BL), which now has an excellent overall outcome. "
03/01/1978 - "Prolonged complete remission following high dose chemotherapy of Burkitt's lymphoma in relapse."
|2.||Combination Drug Therapy (Combination Chemotherapy)
04/01/2006 - "These efforts have led to the development of high-intensity, short-duration combination chemotherapy that has proven extremely effective for a high proportion of Burkitt's lymphoma patients. "
02/01/2012 - "Although polychemotherapy regiments have improved clinical outcome for Burkitt's lymphoma (BL) patients, salvage treatment of patients with refractory disease remains very poor. "
03/01/2012 - "The prognosis of advanced (disseminated) Burkitt lymphoma/leukaemia in children and adolescents three decades ago had a 5-year event-free survival (EFS) of <40%, and required combination chemotherapy and radiation therapy over a 1-2 year period. "
07/01/2005 - "It is this very biology that can dictate the selection of drugs and treatment approaches for managing these patients, strategies that can range from very aggressive combination chemotherapy administered in an intensive care unit (for example, patients with Burkitt's lymphoma), to watch and wait approaches that may go on for years in patients with SLL. "
09/01/2004 - "African Burkitt lymphoma successfully treated with CEOP polychemotherapy."
|3.||Heterologous Transplantation (Xenotransplantation)
03/31/1999 - "To examine the potential efficacy of RFB4(dsFv)-PE38 when administered at a dose schedule appropriate for phase I testing, mice bearing CA46 human CD22+ Burkitt's lymphoma xenografts were treated on alternate days i.v. for 3 doses (QOD x 3). "
01/01/2014 - "The chick chorioallantoic membrane as an in vivo xenograft model for Burkitt lymphoma."
12/15/2005 - "In Raji and Daudi Burkitt lymphoma xenograft models, treatment with a single 5 to 50 microg dose of 2L-Rap-hLL1-gamma4P, given as early or delayed treatment, resulted in cures of most animals. "
02/01/2004 - "Moreover, the antitumor effect of IFN-beta is increased by between 9-fold and 27-fold when injected as an sIFNAR-2-associated complex, as demonstrated by an increase in the mean survival time of immunodeficient mice challenged with human Burkitt lymphoma cell (Daudi) xenografts (sIFNAR-2-complexed vs. free IFN-beta treatment). "
02/01/1992 - "Athymic nude mice bearing human Raji Burkitt lymphoma xenografts were given injections of 2.5 muCi (0.3 microgram) 131I-labeled anti-B1 with or without a 2-h prior single injection of 100 micrograms of unlabeled anti-B1 antibody. "
|4.||Bone Marrow Transplantation (Transplantation, Bone Marrow)
02/01/1988 - "[Allogeneic bone marrow transplantation for Burkitt's lymphoma (stage IV)]."
10/15/1987 - "[Autologous bone marrow transplantation in Burkitt's lymphoma]."
08/01/1986 - "A 5-yr experience of massive therapy and autologous bone marrow transplantation (ABMT) for Burkitt's lymphoma is reviewed. "
08/01/1986 - "Massive therapy and autologous bone marrow transplantation in pediatric and young adults Burkitt's lymphoma (30 courses on 28 patients: a 5-year experience)."
04/01/1986 - "[A successful case of Burkitt's lymphoma treated with allogeneic bone marrow transplantation]."
|5.||Highly Active Antiretroviral Therapy (HAART)
12/01/2002 - "With the discovery of highly active antiretroviral therapy, the ability to treat and control Burkitt's lymphoma in patients with HIV has improved."
04/01/2006 - "Burkitt's lymphoma (BL) increased from 2% in the pre-HAART era (before end-1997) to 13% in the HAART era, whereas incidence of BL did not vary between HAART users and non-users. "
12/01/1998 - "Highly active antiretroviral therapy (HAART) and prolonged survival of a patient with an HIV-related Burkitt lymphoma, despite an intracardiac relapse."
01/01/2012 - "Intensive chemotherapy with CODOX-M/IVAC±R yielded acceptable toxicity and good survival rates in patients with HIV-associated Burkitt lymphoma receiving HAART."
03/27/2010 - ": To retrospectively describe the recovery of cellular immunity and the clinical outcome of 30 patients with HIV-associated Burkitt's lymphoma (HIV-BL), who were treated with the intensive chemotherapy CODOX-M/IVAC and HAART as part of their standard care. "